Background. To describe our experience with the use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) in the treatment of HIV-infected patients in Qatar including both naïve and treatment experienced. We also report the reasons for switching to EVG/COBI/FTC/TAF in treatment-experienced patients, response to treatment, and tolerability. Method. Review of the medical records of the first 100 HIV-infected patients treated with EVG/COBI/FTC/TAF. Results. Among the 100 HIV-infected patients who were treated with EVG/COBI/FTC/TAF, 64 were Qatari and the rest were from other nationalities. 80 patients were males and 20 were females. 29 were treatment naïve, and 71 were treatment experienced. Among treatment-experienced patients, the most common reasons for switch to EVG/COBI/FTC/TAF were safety concerns, followed by regimen simplification and adverse drug reaction of the previous regimen (40%, 14%, and 13%, respectively). Treatment response to EVG/COBI/FTC/TAF leading to undetectable viral load in naïve patients was 69%, and in treatment-experienced patients, it was 83% with an overall response among all patients of 79%. Excluding those who left the country and whose data were not available, the response rate will be 86%. Tolerability was excellent with mild side effects and no discontinuation due to side effects. Conclusion. Experience with the use of EVG/COBI/FTC/TAF in 100 patients with HIV infection in Qatar was favourable both in treatment naïve patients and in those who were treatment experienced with an excellent tolerability.

中文翻译：

---

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 治疗 HIV 感染患者：来自卡塔尔的前 100 名患者的经验。

背景。描述我们在卡塔尔使用 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) 治疗 HIV 感染患者的经验，包括初始治疗和治疗经验。我们还报告了接受过治疗的患者改用 EVG/COBI/FTC/TAF 的原因、对治疗的反应和耐受性。方法。审查接受 EVG/COBI/FTC/TAF 治疗的前 100 名 HIV 感染患者的医疗记录。结果. 在接受 EVG/COBI/FTC/TAF 治疗的 100 名 HIV 感染者中，64 名是卡塔尔人，其余来自其他国籍。80名患者为男性，20名患者为女性。29 人未接受过治疗，71 人接受过治疗。在接受过治疗的患者中，改用 EVG/COBI/FTC/TAF 的最常见原因是安全问题，其次是方案简化和先前方案的药物不良反应（分别为 40%、14% 和 13%）。对 EVG/COBI/FTC/TAF 导致无法检测到病毒载量的初治患者的治疗反应为 69%，在接受过治疗的患者中为 83%，所有患者的总体反应率为 79%。排除那些离开该国且数据不可用的人，回复率为86%。结论。在卡塔尔的 100 名 HIV 感染患者中使用 EVG/COBI/FTC/TAF 的经验对初治患者和接受过良好耐受性治疗的患者都是有利的。